Comparative Pharmacology
Head-to-head clinical analysis: ANDEMBRY versus FERTINEX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ANDEMBRY versus FERTINEX.
ANDEMBRY vs FERTINEX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Binds to androgens, progesterone, and estradiol, inhibiting their effects on hormone-responsive tissues; also binds to microtubules and inhibits tubulin polymerization.
Follitropin beta, a recombinant form of human follicle-stimulating hormone (FSH), binds to the FSH receptor on ovarian granulosa cells and testicular Sertoli cells, stimulating follicular development and maturation in women and spermatogenesis in men.
ANDEMBRY (capivasertib) 400 mg orally twice daily, taken with or without food, in combination with fulvestrant. Continue until disease progression or unacceptable toxicity.
For ovulation induction: 75-150 IU subcutaneously or intramuscularly once daily for 7-12 days; for spermatogenesis: 75-150 IU subcutaneously or intramuscularly 3 times per week.
None Documented
None Documented
Terminal elimination half-life is 12-15 hours in healthy adults; may be prolonged up to 20-25 hours in patients with moderate to severe hepatic impairment.
Terminal elimination half-life is approximately 24-36 hours in patients with normal renal function, supporting once-daily dosing.
Primarily renal excretion of unchanged drug (approximately 70-80%) and as metabolites (10-15%); biliary/fecal elimination accounts for less than 10%.
Primarily renal excretion of unchanged drug (80-90% of administered dose), with the remainder excreted as metabolites in urine and feces.
Category C
Category C
Gonadotropin
Gonadotropin